Mrs Adair Gilliam, OTR | |
12655 Still Pond Ln, Oak Hill, VA 20171-2227 | |
(703) 453-9155 | |
Not Available |
Full Name | Mrs Adair Gilliam |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 12655 Still Pond Ln, Oak Hill, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972922029 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0119002004 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Adair Gilliam, OTR 12655 Still Pond Ln, Oak Hill, VA 20171-2227 Ph: (703) 453-9155 | Mrs Adair Gilliam, OTR 12655 Still Pond Ln, Oak Hill, VA 20171-2227 Ph: (703) 453-9155 |
News Archive
A scientist slides on a pair of plastic 3-D glasses and an unearthly blue multi-armed creature - an image right out of a sci-fi horror flick - seems to leap out of the computer screen into the laboratory.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
The Canadian Breast Cancer Foundation - Atlantic announced today a first-of-its-kind partnership between the breast screening programs of Nova Scotia and Newfoundland and Labrador that yield benefits that could extend to the rest of Canada and beyond.
Researchers from the Department of Pharmacy at the University of Copenhagen have developed a cell line, which may be used to investigate new drugs and help predict whether they are able to enter the brain.
A new general medical journal launched this week with a non-traditional publishing model is the latest top-tier venue for publishing important, peer-reviewed biomedical research, and is being called the first major, international journal to be introduced in more than 70 years.
› Verified 7 days ago